课题基金 / 基金详情

Preclinical evaluation of HIV-1 envelope immunogens in humanized mice

Preclinical evaluation of HIV-1 envelope immunogens in humanized mice
HIV-1包膜免疫原在人源化小鼠中的临床前评估
批准号:
10667351
负责人:
VIKRAM SRIVASTAVA
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-07-01 至 2023-06-30

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
用于HIV候选疫苗临床前评价的基因工程小鼠:新型HIV候选疫苗的开发通常需要在动物模型中进行临床前试验,然后再进行I期临床试验。多种努力集中在开发和评估用于诱导和产生持久和广泛中和抗体(bNAb)应答的HIV包膜(Env)免疫原的创新平台和制剂上。该计划的目标是利用基因工程小鼠模型,如人免疫球蛋白KI或其他表达相关人类基因的转基因小鼠,以加速HIV候选疫苗的测试和开发。
英文摘要
Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates: The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focused on developing and evaluating innovative platforms and formulations of HIV envelope (Env) immunogens for the induction and generation of a durable and broadly neutralizing antibody (bNAb) response. The goal of this program is to utilize genetically engineered mouse models, such as human immunoglobulin KI or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金